急性心肌梗死(AMI)早期溶栓治疗使血管再通,可明显降低病死率并改善生存者左心室功能。但溶栓治疗有许多限制:仅有约1/3的AMI患者适宜接受溶栓治疗,而不适宜溶栓治疗者的病死率大大高于适宜溶栓治疗者;不论何种溶栓剂、采用何种给药方法,用药后90分钟的血管通畅率最高为85％,达到TIMI3级血流者至多为50％～55％;由于溶栓治疗后存在残余狭窄,约15％～30％患者缺血复发,且 Early thrombolytic therapy of acute myocardial infarction (AMI) renovates blood vessels and significantly reduces mortality and improves left ventricular function in survivors. However, thrombolytic therapy has many limitations: only about one-third of AMI patients are eligible for thrombolytic therapy, whereas unsuitable thrombolytic therapy patients have a significantly higher case-fatality rate than thrombolytic therapy; regardless of the thrombolytic agent, What kind of drug delivery method, 90 minutes after administration of vascular patency up to 85%, up to TIMI3 grade blood flow were up to 50% to 55%; due to residual stenosis after thrombolytic therapy, about 15% to 30% of patients missing Blood recurrence, and